• Something wrong with this record ?

Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO

V. Annese, D. Duricova, C. Gower-Rousseau, T. Jess, E. Langholz,

. 2016 ; 10 (2) : 216-25. [pub] 20151031

Language English Country England, Great Britain

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc17000904

The medical management of inflammatory bowel disease has changed considerably over time with wider use of immunosuppressant therapy and the introduction of biological therapy. To what extent this change of medical paradigms has influenced and modified the disease course is incompletely known. To address this issue, an extensive review of the literature has been carried out on time trends of hospitalization, surgery, infections, cancer, and mortality rates in inflammatory bowel disease [IBD] patients. Preference was given to population-based studies but, when data from these sources were limited, large cohort studies and randomised controlled trials were also considered. In general, data on hospitalisation rates are strikingly heterogeneous and conflicting. In contrast, the consistent drop in surgery/colectomy rates suggests that the growing use of immunosuppressants and biological agents has had a positive impact on the course of IBD. Most clinical trial data indicate that the risk of serious infections is not increased in patients treated with anti-tumour necrosis factor alpha [TNFα] agents, but a different picture emerges from cohort studies. The use of thiopurines increases the risk for non-melanoma skin cancers and to a lesser extent for lymphoma and cervical cancer [absolute risk: low], whereas no clear increase in the cancer risk has been reported for anti-TNF agents. Finally, the majority of studies reported in the literature do not reveal any increase in mortality with immunosuppressant therapy or biologicals/anti-TNF agents.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000904
003      
CZ-PrNML
005      
20170118114044.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ecco-jcc/jjv190 $2 doi
024    7_
$a 10.1093/ecco-jcc/jjv190 $2 doi
035    __
$a (PubMed)26520163
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Annese, Vito $u Emergency Department, Gastroenterology Unit, AOU Careggi, Florence, Italy annesev@aou-careggi.toscana.it. $7 gn_A_00007133
245    10
$a Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO / $c V. Annese, D. Duricova, C. Gower-Rousseau, T. Jess, E. Langholz,
520    9_
$a The medical management of inflammatory bowel disease has changed considerably over time with wider use of immunosuppressant therapy and the introduction of biological therapy. To what extent this change of medical paradigms has influenced and modified the disease course is incompletely known. To address this issue, an extensive review of the literature has been carried out on time trends of hospitalization, surgery, infections, cancer, and mortality rates in inflammatory bowel disease [IBD] patients. Preference was given to population-based studies but, when data from these sources were limited, large cohort studies and randomised controlled trials were also considered. In general, data on hospitalisation rates are strikingly heterogeneous and conflicting. In contrast, the consistent drop in surgery/colectomy rates suggests that the growing use of immunosuppressants and biological agents has had a positive impact on the course of IBD. Most clinical trial data indicate that the risk of serious infections is not increased in patients treated with anti-tumour necrosis factor alpha [TNFα] agents, but a different picture emerges from cohort studies. The use of thiopurines increases the risk for non-melanoma skin cancers and to a lesser extent for lymphoma and cervical cancer [absolute risk: low], whereas no clear increase in the cancer risk has been reported for anti-TNF agents. Finally, the majority of studies reported in the literature do not reveal any increase in mortality with immunosuppressant therapy or biologicals/anti-TNF agents.
650    _2
$a chirurgie trávicího traktu $x trendy $7 D013505
650    _2
$a celosvětové zdraví $7 D014943
650    _2
$a hospitalizace $x trendy $7 D006760
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a infekce $x epidemiologie $x etiologie $7 D007239
650    12
$a idiopatické střevní záněty $x komplikace $x mortalita $x terapie $7 D015212
650    _2
$a hodnocení rizik $x metody $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a míra přežití $x trendy $7 D015996
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Duricova, Dana $u Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE a.s. and Charles University in Prague, Prague, Czech Republic.
700    1_
$a Gower-Rousseau, Corinne $u Epidemiology Unit, Lille University and Hospital, Université Lille Nord de France, Lille, France.
700    1_
$a Jess, Tine $u Department of Epidemiology Research, Statens Serum Institut, National Center for Health Data and Disease Control, Copenhagen, Denmark.
700    1_
$a Langholz, Ebbe $u Department of Medicine, Gentofte Hospital, Hellerup, Denmark.
773    0_
$w MED00166945 $t Journal of Crohn's & colitis $x 1876-4479 $g Roč. 10, č. 2 (2016), s. 216-25
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26520163 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170118114151 $b ABA008
999    __
$a ok $b bmc $g 1180044 $s 961471
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 10 $c 2 $d 216-25 $e 20151031 $i 1876-4479 $m Journal of Crohn's and colitis $n J Crohns Colitis $x MED00166945
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Archiving options